Inclusion Criteria:

          -  Signed informed consent document on file;

          -  Age over 60 years;

          -  Age < 60 years and amenorrheic for 12 or more months in the absence of chemotherapy,
             tamoxifen, toremifene, or ovarian suppression and FSH and oestradiol level in the
             postmenopausal range;

          -  Patients with metastatic or locally advanced disease not amenable to therapy with
             Curative intent

          -  ER + and/or PgR +;

          -  Duration of adjuvant non-aromatase inhibitors treatment should be at least 2 years or
             more;

          -  WHO performance status 0, 1 or 2;

          -  Patients with life expectancy of more than 3 months.

        Exclusion Criteria:

          -  Presence of life-threatening metastatic visceral disease;

          -  Previous systemic chemotherapy for advanced breast cancer;

          -  Received systemic endocrine therapy for advanced disease;

          -  Extensive radiation therapy within the last 4 weeks ;

          -  Platelets < 100*109 / L,Total bilirubin no less than 1.5ULRR, ALT or AST no less than
             2.5ULRR if no demonstrable liver metastases or no less than 5ULRR in presence of liver
             metastases;

          -  Severe renal impairment, bleeding diathesis, long-term anticoagulant therapy;

          -  History of hypersensitivity to active or inactive excipients of fulvestrant,
             Exemestane and/or castor oil.